CLAIM #22622 · EMR (EMR) · 2023Q4 earnings call · Nov 7, 2023 · due Sep 30, 2024
“That is our expectation, yes sir.”
Lal Karsanbhai · CEO
In context
“cles and that will impact how we should think about the strength of process as we go through 2024. Ram, you have something to add? Ram Krishnan: Yeah, and the other point I'd make, Julian, is the capital spend in the process hybrid industries has been pretty disciplined. There hasn't been a boom in capital to cause a correction as we move forward as opposed to the prior cycles we saw. So I think that disciplined capital spend plus obviously the trends that Lal identified where the sustainability investments provide that tailwind, we expect process to continue to run for a lot longer. Julian Mitchell: I see, so you… Lal Karsanbhai: Process and hybrid -- and hybrid, yeah. Julian Mitchell: Got it. So the process and hybrid orders growth should stay fairly steady through 2024. Lal Karsanbhai: That is our expectation, yes sir. Julian Mitchell: Fantastic. Thanks for the help. Lal Karsanbhai: Thanks, Julian. Operator: The next question comes from Nigel Coe with Wolfe Research. Please go ahead. Nigel, your line is now live. Nigel Coe: Okay. The line is live, but I'm not, so sorry for that. So National Instruments, I think that the 4Q fiscal sales were down, I think, high single-digit, organic. Is that the right number? Is my math correct? And it looks like the guide implies flattish to maybe slightly down organic. Just wondering what the profile is on that and anything on orders there would be helpful. Ram Krishnan: Yeah. So, Ram here, Nigel. From an orders perspective, as Lal indicated, the last quarter, which is our fourth quarter, down 16% in orders, we expect orders to remain down for the first half and turn p”
Verify independently
SEC filings for EMR ↗ · Claim quote is verbatim from the 2023Q4 earnings call.